PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in several prominent conferences, where it will present significant findings related to its lead candidate, INO-3107. The presentations will underscore the company’s progress in developing DNA medicines for treating recurrent respiratory papillomatosis (RRP) and other virally-mediated diseases.
Key data on INO-3107, which achieved a 72% overall response rate in the first year for RRP caused by HPV-6 and HPV-11, will be highlighted during the inaugural National HPV Conference in Indianapolis on April 15. Kim McClellan, RRP Foundation President, will moderate a panel addressing lessons learned and clinical advances related to the disease.
At the World Vaccine Congress in Washington, DC, INOVIO will deliver two oral presentations, including one titled “A New Frontier in mAb Therapeutics,” showcasing advancements in DNA-encoded monoclonal antibody (DMAb™) technology on April 21. The company will also spotlight the broader applications of DNA immunotherapeutics on April 23.
The Festival of Biologics in San Diego, also on April 23, will provide another platform for INOVIO to present groundbreaking data on INO-3107 and its potential to transform treatment for RRP.
These presentations reflect INOVIO’s ongoing commitment to advancing DNA medicine in treating virally-mediated diseases and cancers, signaling a step forward in medical innovation. Abstracts will be made available on the company’s website following the events.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.